Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 8/20 | 0.74 |
| ▸ | MCHR1 | Q99705 | 10/20 | 0.67 |
| ▸ | MCHR2 | Q969V1 | 2/20 | 0.65 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6109760 | 0.99 | EPHX2 (0.75) | EPHX2MCHR1MCHR2 | |
| SCHEMBL6108709 | 0.94 | MCHR1 (0.76) | EPHX2MCHR1MCHR2HTR4 | |
| SCHEMBL6108737 | 0.94 | MCHR1 (0.74) | EPHX2MCHR1MCHR2HTR4 | |
| SCHEMBL6110622 | 0.91 | EPHX2 (0.77) | EPHX2MCHR1 | |
| SCHEMBL6108942 | 0.90 | MCHR1 (0.81) | EPHX2MCHR1MCHR2 | |
| SCHEMBL6109144 | 0.89 | MCHR1 (0.68) | EPHX2MCHR1MCHR2HTR4 | |
| SCHEMBL6109301 | 0.88 | MCHR1 (0.68) | EPHX2MCHR1MCHR2HTR4 | |
| SCHEMBL6110881 | 0.87 | MCHR1 (0.84) | EPHX2MCHR1MCHR2HTR4 | |
| SCHEMBL6109200 | 0.87 | MCHR1 (0.65) | EPHX2MCHR1MCHR2 | |
| SCHEMBL6108746 | 0.87 | MCHR1 (0.75) | EPHX2MCHR1MCHR2HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060235035-A1 | Novel methoxybenzamibe compounds for use in mch receptor related disorders | 7TM PHARMA A/S (DK) | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235035-A1 | Novel methoxybenzamibe compounds for use in mch receptor related disorders | GPR119, MCHR2, HCRTR2 | EPHX2 2527/4885MCHR1 5/4885MCHR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.